Open Access

ARTICLE

Role of PTX3 and complement modulation in the tumor microenvironment

GIUSEPPE STEFANO NETTI^1,*, FEDERICA SPADACCINO¹, VALERIA CATALANO¹, GIUSEPPE CASTELLANO², GIOVANNI STALLONE³, ELENA RANIERI¹

1 Clinical Pathology Unit and Center for Molecular Medicine, Department of Medical and Surgical Sciences, University of Foggia, Foggia, 71122, Italy
2 Nephrology, Dialysis and Renal Transplant Unit, Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico-University of Milan, Milan, 20122, Italy
3 Nephrology Dialysis and Transplantation Unit, Advanced Research Center on Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University of Foggia, Foggia, 71122, Italy

* Corresponding Author: Giuseppe Stefano Netti,

(This article belongs to the Special Issue: Tumor Microenvironment and Cytoskeletal Dynamics)

BIOCELL 2022, 46(10), 2235-2239. https://doi.org/10.32604/biocell.2022.020209

Received 23 December 2021; Accepted 17 February 2022; Issue published 13 June 2022

Abstract

Pentraxin-3 (PTX3), the prototype of long pentraxins, seems to influence complement system (CS) modulation. PTX3 and CS sustain carcinogenesis, enriching tumor microenvironment (TME) with pro-inflammatory molecules promoting angiogenesis in prostate cancer (PC) and renal cell carcinoma (RCC). Furthermore, cancer cells overexpress complement regulatory proteins, such as CD46, CD55 and CD59, which negatively affect complement pathways for support cancer cells survival. This viewpoint aims to elucidate the ambivalent role of PTX3 and the CS in the context of tumor microenvironment (TME).

---

Keywords

---